GSK plc (GSK,GSK.L) announced the FDA has approved Blenrep in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The Blenrep approval is supported by data from the pivotal DREAMM-7 phase III trial.
Blenrep is available through a new, streamlined Risk Evaluation and Mitigation Strategy. GSK will offer Together with GSK, an optional patient support programme available to all US patients prescribed Blenrep.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.